Our fully automated wet lab that generates superior quality data at scale, feeding into our data lake and powering our decision-making from target to hit, lead, and candidate.
Better data today.
Better drugs tomorrow.
Arctoris® is a tech-enabled biopharma company
Drug discovery has to change — and we reimagine the path from target to hit, lead, and candidate by leveraging the power of Ulysses®, our unique, integrated drug discovery platform.
The future of drug discovery is data-driven
Data is the lifeblood of research, and better data leads to better decisions.
We combine robotics, data science, and machine learning to make better decisions based on robust, reliable, and reproducible data both for our wholly-owned and our partnered programs. Our platform enables us to make the right decisions at the right time, and move novel programs towards the clinic faster.
Arctoris is revolutionizing the R&D process
Our unique strengths
Our integrated data architecture that captures and analyzes experimental data in real-time, closing the loop with advanced machine learning algorithms.
Our world-class team of seasoned drug hunters, experienced engineers, and leading machine learning scientists that guides our discovery work.
Who we partner with
We work with select biotech companies, pharmaceutical corporations, and AI drug discovery companies from across the world to bring new drugs to patients faster.
What our partners are saying
“Having visited their robotic lab in Oxford, I know that this is the future of drug discovery. In addition to their remarkable facility, I continue to be impressed by the depth of scientific expertise of the Arctoris team.”
"We have been working with Arctoris on several projects, and they are our go-to solution for new work coming up. The data quality they provide us with using their automated system is fantastic."
“Arctoris’ automated lab and scientific expertise led us to validate our AI-derived drug targets in robust industry-standard assays in an extremely time-efficient manner. Our partnership with Arctoris was fuelled by in-depth scientific discussions, and led to highly significant results.”
“The automated assay developed by Arctoris is sensitive enough to distinguish antibodies at 1nM potency - this makes a huge difference to our company, and will be extremely helpful for anyone involved with antibody research.”
What we’ve been up to
Cyclica and Arctoris to expand partnership to advance drug discovery programs for Alzheimer's disease
Read moreIBM Research and Arctoris accelerate closed loop drug discovery with AI and Cloud
Read moreWhy Should You Automate Your Experiments?
Read moreArctoris and Evariste Technologies form a Joint Venture to Identify Novel Small Molecule cMET Inhibitors for Non-Small Cell Lung Cancer
Read moreRole of Pharma Companies in the AI-enabled Drug Discovery Landscape
Read moreDriving the evolution of AI-enabled drug discovery - a global perspective
Read moreArctoris Celebrates 5th Anniversary and Launches Its Expanded Robotic Platform Ulysses
Read moreCelebrating Five Years of Arctoris
Read more5 Myths About Laboratory Automation
Read moreYoung Scholars at a Young Company: Meet our Interns
Read moreBiology 2.0: Combining machine-learning, robotics and biology to deliver drug discovery of tomorrow
Read moreFrom Eroom’s Law to Moore’s Law: Drug Discovery in the 21st Century
Read moreShould I Automate My Cellular Assay?
Read moreLet’s build the future of drug discovery together
We are always on the look-out for new partnerships, in/out-licensing and co-development opportunities where we can leverage our platform for accelerated drug discovery and development.The latest in AI drug discovery
To keep up with the latest news and important developments in AI drug discovery, subscribe here to receive the quarterly Arctoris Report prepared by our experts
